Rein Therapeutics, Inc. (RNTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 12407 N. MOPAC EXPY.
AUSTIN, TX 78758
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,215,00012,865,00017,313,00021,242,00045,933,00013,805,000
Cash and cash equivalent3,215,00012,865,00017,313,0005,194,0003,600,0007,046,000
Short-term investments    16,048,00042,333,0006,759,000
Restricted cash and investments   25,00025,00025,000593,000
Other current assets881,000676,000675,000   
Other undisclosed current assets230,000116,000253,000606,0002,219,0001,928,000
Total current assets:4,326,00013,657,00018,266,00021,873,00048,177,00016,326,000
Noncurrent Assets
Operating lease, right-of-use asset    40,000152,000 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  1,00019,00070,000128,00015,000
Intangible asset, including goodwill, after accumulated amortization19,830,00048,530,00085,530,000   
Goodwill6,330,0006,330,0006,330,000   
Intangible asset, excluding goodwill, after accumulated amortization13,500,00042,200,00079,200,000   
Other noncurrent assets2,0002,0002,193,00024,00024,000 
Total noncurrent assets:19,832,00048,533,00087,742,000134,000304,00015,000
TOTAL ASSETS:24,158,00062,190,000106,008,00022,007,00048,481,00016,341,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,317,0002,907,0003,021,0002,637,0002,780,0002,653,000
Employee-related liabilities✕✕✕✕✕1,182,000922,000
Accounts payable3,976,000911,0001,190,0001,720,0001,210,0001,596,000
Accrued liabilities1,341,0001,996,0001,831,000917,000388,000135,000
Debt      
Other undisclosed current liabilities863,0002,842,0001,364,000747,0001,728,0001,307,000
Total current liabilities:6,180,0005,749,0004,385,0003,384,0004,508,0003,960,000
Noncurrent Liabilities
Long-term debt and lease obligation:     69,000 
Liabilities, other than long-term debt1,060,0002,049,0003,326,000   
Deferred income tax liabilities1,060,0001,772,0003,326,000   
Other liabilities  277,000    
Operating lease, liability     69,000 
Other undisclosed noncurrent liabilities     (69,000)219,000
Total noncurrent liabilities:1,060,0002,049,0003,326,000 69,000219,000
Total liabilities:7,240,0007,798,0007,711,0003,384,0004,577,0004,179,000
Temporary equity, including noncontrolling interest45,005,00045,005,00091,410,000   
Equity
Equity, attributable to parent, including:16,918,00054,392,0006,887,00018,623,00043,904,00012,162,000
Common stock113,000108,00091,00091,00091,00044,000
Additional paid in capital373,133,000360,697,000295,376,000291,365,000289,282,000231,412,000
Accumulated other comprehensive loss(62,000)(18,000)(63,000)(48,000)(13,000)(2,000)
Accumulated deficit(401,271,000)(351,400,000)(288,517,000)(272,785,000)(245,456,000)(219,292,000)
Other undisclosed equity, attributable to parent45,005,00045,005,000    
Other undisclosed equity(45,005,000)(45,005,000)    
Total equity:(28,087,000)9,387,0006,887,00018,623,00043,904,00012,162,000
TOTAL LIABILITIES AND EQUITY:24,158,00062,190,000106,008,00022,007,00048,481,00016,341,000

Income Statement (P&L) (USD)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(50,631,000)(65,112,000)(16,276,000)(27,647,000)(26,605,000)(20,496,000)
Operating loss:(50,631,000)(65,112,000)(16,276,000)(27,647,000)(26,605,000)(20,496,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
48,000685,000544,000318,000441,000(661,000)
Loss from continuing operations before income taxes:(50,583,000)(64,427,000)(15,732,000)(27,329,000)(26,164,000)(21,157,000)
Income tax benefit 712,0001,544,000    
Other undisclosed income from continuing operations      
Loss from continuing operations:(49,871,000)(62,883,000)(15,732,000)(27,329,000)(26,164,000)(21,157,000)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(26,164,000)(21,157,000)
Net loss available to common stockholders, diluted:(49,871,000)(62,883,000)(15,732,000)(27,329,000)(26,164,000)(21,157,000)

Comprehensive Income (USD)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(49,871,000)(62,883,000)(15,732,000)(27,329,000)(26,164,000)(21,157,000)
Comprehensive loss:(49,871,000)(62,883,000)(15,732,000)(27,329,000)(26,164,000)(21,157,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(44,000)45,000(15,000)(35,000)(11,000)(9,000)
Comprehensive loss, net of tax, attributable to parent:(49,915,000)(62,838,000)(15,747,000)(27,364,000)(26,175,000)(21,166,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: